Small Cell Carcinoma of the Esophagus Treated with Esophagectomy and following Chemotherapy: Case Report with Review of the Literature

Usami, Shuetsu; Motoyama, Satoru; Maruyama, Kiyotomi; Sato, Yu; Shibuya, Kaori; Nakatsu, Toshinobu; Saito, Haruo; Minamiya, Yoshihiro; Ogawa, Jun–ichi

doi:10.1159/000318589

Cited by 4 publications

(3 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The principle of the operation is to remove the primary tumor as far as possible and to clean up all the metastatic lymph nodes and metastases. 24 There is currently no consensus regarding the treatment of SCNEC of the esophagus, which may be related to the lack of a large number of cases and large-scale clinical studies. In recent years, as the number of treatments has increased and treatment experience has accumulated, the importance of operations has been accepted and multidisciplinary treatment modalities including surgical treatment and postoperative adjuvant chemotherapy have received more and more attention.…”

Section: Surgical Treatmentmentioning

confidence: 99%

See 1 more Smart Citation

Progress in the treatment of esophageal neuroendocrine carcinoma

Cai

Cui

2017

Tumour Biol.

View full text Add to dashboard Cite

Esophageal neuroendocrine neoplasms are rare. With the improvement and popularization of diagnostic methods, the morbidity statistics have increased annually in recent years. There are currently no treatment guidelines for esophageal neuroendocrine neoplasms, and surgery is the only cure. This usually involves radical surgery when the tumor is limited to the primary site or when only regional lymph node metastasis occurs. Surgical treatment is key to treating esophageal neuroendocrine neoplasms, but combined treatment with chemotherapy and radiotherapy can significantly improve patient survival. The effect of radiotherapy alone on this disease is poor. However, targeted endocrine therapy can improve endocrine hormone symptoms. The prognosis of patients with esophageal neuroendocrine neoplasms is mainly determined by the pathological stage. With the development of molecular biology techniques, the combination of targeted drugs and traditional chemotherapy is expected to provide novel ideas and directions for the treatment of esophageal neuroendocrine neoplasms in the coming years. In this article, the status of esophageal neuroendocrine tumor treatments was reviewed in detail.

show abstract

Section: Surgical Treatmentmentioning

confidence: 99%

“…The principle of the operation is to remove the primary tumor as far as possible and to clean up all the metastatic lymph nodes and metastases. 24…”

Section: Treatmentmentioning

confidence: 99%

Progress in the treatment of esophageal neuroendocrine carcinoma

Cai

Cui

2017

Tumour Biol.

View full text Add to dashboard Cite

show abstract

“…The role of surgery is undecided, but due to an operational mortality risk, it is generally agreed that surgery should only be performed when of clear survival benefit [ 188 ], for example in localized cases [ 160 ], and preferably with adjuvant chemotherapy due to the risk of recurrence with distant metastases [ 141 ]. It has been shown in a number of studies that lymph node metastases are a significant prognostic factor in patients receiving surgery as first line treatment [ 139 ], and if radical surgery and adjuvant chemotherapy are given to patients without lymph metastases or patients with limited disease, relatively good long-term survival can be achieved [ 139 , 146 , 149 , 151 , 163 , 165 , 180 , 188 ]. A study from Hou et al [ 143 ] showed that the combination of surgery and radiotherapy could give a median survival of 23 months in limited stage SCEC, and if chemotherapy was added, survival time increased to 25 months.…”

Section: Oesophagusmentioning

confidence: 99%

Neuroendocrine Carcinomas of the Gastroenteropancreatic System: A Comprehensive Review

et al. 2015

View full text Add to dashboard Cite

To date, empirical literature has generally been considered lacking in relation to neuroendocrine carcinomas (NECs), the highly malignant subgroup of neuroendocrine neoplasms. NECs are often found in the lungs or the gastroenteropancreatic (GEP) system and can be of small or large cell type. Concentrating on GEP-NECs, we can conclude that survival times are poor, with a median of only 4–16 months depending on disease stage and primary site. Further, this aggressive disease appears to be on the rise, with incidence numbers increasing while survival times are stagnant. Treatment strategies concerning surgery are often undecided and second-line chemotherapy is not yet established. After an analysis of over 2600 articles, we can conclude that there is indeed more empirical literature concerning GEP-NECs available than previously assumed. This unique review is based on 333 selected articles and contains detailed information concerning all aspects of GEP-NECs. Namely, the classification, histology, genetic abnormalities, epidemiology, origin, biochemistry, imaging, treatment and survival of GEP-NECs are described. Also, organ-specific summaries with more detail in relation to disease presentation, diagnosis, treatment and survival are presented. Finally, key points are discussed with directions for future research priorities.

show abstract